Xavier Leleu
沙维尔·勒卢
MD, PhD
Professor of Hematology, Head of Hematology and Cell Therapy Department血液学教授，血液学及细胞治疗科主任
👥Biography 个人简介
Dr. Xavier Leleu is a leading French hematologist specializing in multiple myeloma and Waldenström macroglobulinemia. He has contributed extensively to clinical trials on novel agents including BTK inhibitors, proteasome inhibitors, and immunomodulatory drugs in both diseases, and leads major European cooperative studies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Waldenström Macroglobulinemia Therapy
Conducted pivotal trials on ibrutinib and zanubrutinib in Waldenström macroglobulinemia, defining BTK inhibitor-based therapy as the standard for this rare lymphoplasmacytic malignancy.
Novel Agents in Myeloma
Led early-phase trials evaluating new proteasome inhibitors and IMiDs in relapsed/refractory myeloma, advancing therapeutic options for heavily pretreated patients.
Representative Works 代表性著作
Ibrutinib in Previously Treated Waldenström Macroglobulinemia
New England Journal of Medicine (2015)
Demonstrated high response rates with ibrutinib in relapsed Waldenström macroglobulinemia, leading to regulatory approval of the BTK inhibitor.
Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Blood (2016)
Established KRd triplet efficacy in relapsed myeloma with robust overall response rates and acceptable safety.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 沙维尔·勒卢 的研究动态
Follow Xavier Leleu's research updates
留下邮箱，当我们发布与 Xavier Leleu（University Hospital of Poitiers, Université de Poitiers）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment